PMID- 31366174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 8
DP  - 2019 Jul 30
TI  - Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to 
      High-Dimensional Analyses.
LID - 10.3390/cancers11081082 [doi]
LID - 1082
AB  - The interaction between tumor cells and the immune system is considered to be a 
      dynamic process. Dendritic cells (DCs) play a pivotal role in anti-tumor immunity 
      owing to their outstanding T cell activation ability. Their functions and 
      activities are broad ranged, triggering different mechanisms and responses to the 
      DC subset. Several studies identified in situ human tumor-infiltrating DCs by 
      immunostaining using a limited number of markers. However, considering the 
      heterogeneity of DC subsets, the identification of each subtype present in the 
      immune infiltrate is essential. To achieve this, studies initially relied on flow 
      cytometry analyses to provide a precise characterization of tumor-associated DC 
      subsets based on a combination of multiple markers. The concomitant development 
      of advanced technologies, such as mass cytometry or complete transcriptome 
      sequencing of a cell population or at a single cell level, has provided further 
      details on previously identified populations, has unveiled previously unknown 
      populations, and has finally led to the standardization of the DCs classification 
      across tissues and species. Here, we review the evolution of tumor-associated DC 
      description, from in situ visualization to their characterization with 
      high-dimensional technologies, and the clinical use of these findings 
      specifically focusing on the prognostic impact of DCs in cancers.
FAU - Hubert, Margaux
AU  - Hubert M
AD  - Cancer Research Center Lyon, UMR INSERM 1052 CNRS 5286, Centre Leon Berard, 28 
      rue Laennec, 69373 Lyon, France.
FAU - Gobbini, Elisa
AU  - Gobbini E
AD  - Cancer Research Center Lyon, UMR INSERM 1052 CNRS 5286, Centre Leon Berard, 28 
      rue Laennec, 69373 Lyon, France.
FAU - Bendriss-Vermare, Nathalie
AU  - Bendriss-Vermare N
AD  - Cancer Research Center Lyon, UMR INSERM 1052 CNRS 5286, Centre Leon Berard, 28 
      rue Laennec, 69373 Lyon, France.
FAU - Caux, Christophe
AU  - Caux C
AD  - Joint first author..
FAU - Valladeau-Guilemond, Jenny
AU  - Valladeau-Guilemond J
AD  - Joint first author.. jenny.valladeau@lyon.unicancer.fr.
LA  - eng
GR  - fellowship/European Society for Medical Oncology/
GR  - 4th year PhD/Fondation ARC pour la Recherche sur le Cancer/
GR  - CRCL/Institut National de la Sante et de la Recherche Medicale/
GR  - PLBIO INCa_4508/Institut National Du Cancer/
GR  - Auvergne-Rhone-Alpes/Ligue Contre le Cancer/
GR  - Saone et Loire/Ligue Contre le Cancer/
GR  - Comite de Savoie/Ligue Contre le Cancer/
GR  - LYRICAN, grant no. INCa_4664/SIRIC project/
GR  - ANR-10-LABX-0061/LABEX DEVweCAN/
PT  - Journal Article
PT  - Review
DEP - 20190730
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6721288
OTO - NOTNLM
OT  - RNA-seq
OT  - cytometry
OT  - dendritic cells
OT  - immune signatures
OT  - prognosis
OT  - single cell RNA-seq
COIS- The authors declare no conflict of interest.
EDAT- 2019/08/02 06:00
MHDA- 2019/08/02 06:01
PMCR- 2019/07/30
CRDT- 2019/08/02 06:00
PHST- 2019/06/20 00:00 [received]
PHST- 2019/07/17 00:00 [revised]
PHST- 2019/07/22 00:00 [accepted]
PHST- 2019/08/02 06:00 [entrez]
PHST- 2019/08/02 06:00 [pubmed]
PHST- 2019/08/02 06:01 [medline]
PHST- 2019/07/30 00:00 [pmc-release]
AID - cancers11081082 [pii]
AID - cancers-11-01082 [pii]
AID - 10.3390/cancers11081082 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Jul 30;11(8):1082. doi: 10.3390/cancers11081082.